V
Vaxcyte, Inc. (PCVX)
NMS – Real vaqt narxi. Valyuta: USD
54.03
+0.04 (0.07%)
Yopilishda: May 12, 2026, 4:00 PM EDT
55.46
+1.43 (2.65%)
Bozor oldidan: May 13, 2026, 5:07 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
54.03
+0.04 (0.07%)
Yopilishda: May 12, 2026, 4:00 PM EDT
55.46
+1.43 (2.65%)
Bozor oldidan: May 13, 2026, 5:07 AM EDT
Vaxcyte, Inc., klinik bosqichdagi vaktsina innovatsiyalari kompaniyasi, bakterial yuqumli kasalliklarning oldini olish yoki davolash uchun kon'yugat va yangi oqsil vaktsinalarini ishlab chiqadi. Uning yetakchi vaktsina nomzodi VAX-24 bo'lib, bu chaqaloqlarda invaziv pnevmoniya kasalligining (IPD) oldini olish uchun 24 valentli, tashuvchisiz, tadqiqotdagi pnevmoniya kon'yugat vaktsinasi (PCV) hisoblanadi. Kompaniya, shuningdek, kattalar va bolalarda IPDning oldini olish uchun 31 valentli, tashuvchisiz, tadqiqotdagi PCV bo'lgan VAX-31; A guruhi streptokokklari keltirib chiqaradigan kasallikning oldini olish uchun yangi kon'yugat vaktsina nomzodi bo'lgan VAX-A1; parodontitga sabab bo'lgan asosiy patogenga qaratilgan yangi oqsil vaktsina nomzodi bo'lgan VAX-PG; Shigella bakteriyalari keltirib chiqaradigan dizenteriya va shigellyozni davolash uchun yangi preklinik vaktsina nomzodi bo'lgan VAX-GI; va uchinchi avlod pnevmoniya kon'yugat vaktsinasi bo'lgan VAX-XLni ishlab chiqadi. Kompaniya ilgari SutroVax, Inc. nomi bilan tanilgan va 2020-yil may oyida Vaxcyte, Inc. nomini olgan. Vaxcyte, Inc. 2013-yilda ro'yxatga olingan va shtab-kvartirasi Kaliforniyaning San-Karloss shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research |
| Mr. Andrew L. Guggenhime M.B.A. | President & CFO |
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director |
| Mr. Harp Dhaliwal M.B.A. | Chief Technical Operations Officer |
| Mr. James T. Wassil M.B.A., M.S. | Executive VP & COO |
| Mr. Jeff Macdonald | Executive Director of Investor Relations |
| Mr. Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary |
| Ms. Elvia Cowan | Senior VP of Finance & Chief Accounting Officer |
| Ms. Janet Graesser | Senior Vice President of Corporate Affairs |
| Ms. Whitney Jones | Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 10-Q | pcvx-20260331.htm |
| 2026-04-23 | DEFA14A | d945804ddefa14a.htm |
| 2026-02-24 | 8-K | pcvx-20260224.htm |
| 2026-02-24 | 10-K | pcvx-20251231.htm |
| 2026-02-02 | 8-K | d54534d8k.htm |
| 2025-12-19 | 8-K | pcvx-20251218.htm |
| 2025-11-04 | 8-K | pcvx-20251104.htm |
| 2025-09-30 | 8-K | pcvx-20250924.htm |
| 2025-08-06 | 10-Q | pcvx-20250630.htm |
| 2025-06-17 | 8-K | pcvx-20250612.htm |